Clinically, glycemic variability, hypoglycemia followed by rebound hyperglycemia, induced by exogenous insulin or insulin secretagogues may amplify the tumor-promoting potential of these pathways, in a tumor type–dependent manner (28, 29). This evidence concerns the gene INS and neoplasm.